Which mutual funds hold Tatva Chintan Pharma Chem?
5 Direct Growth mutual fund schemes held Tatva Chintan Pharma Chem (Materials) at the end of Aug 2026, 1 fewer than in Jul 2026. The largest position was in JM Multi Asset Allocation Fund, at 0.63% of the scheme.
- Schemes holding
- 5
- New entries
- 0
- Fully exited
- 1
- Increased
- 0
- Decreased
- 0
- Average weight
- 0.48%
By fund type: Equity 4 · Hybrid 1
What changed in Aug 2026
vs Jul 2026 · by number of sharesFully exited (1)
- Motilal Oswal BSE 1000 Index Fund Equity Index0.01%
Weight shown as last month → this month. Only the 1,622 schemes with portfolios for both months are compared.
All 5 schemes holding Tatva Chintan Pharma Chem
Sorted by weight in the scheme| # | Scheme | Category | Weight | Shares | This month |
|---|---|---|---|---|---|
| 1 | JM Multi Asset Allocation Fund JM Financial | Multi Asset Allocation | 0.63% | 6,182 | Unchanged |
| 2 | ICICI Prudential MNC Fund ICICI Prudential | Sectoral / Thematic | 0.60% | 67,089 | Unchanged |
| 3 | Nippon India | ELSS (Tax Saver) | 0.57% | 5,16,700 | Unchanged |
| 4 | WhiteOak Capital Pharma and Heathcare Fund WhiteOak Capital | Sectoral / Thematic | 0.39% | 21,576 | Unchanged |
| 5 | ICICI Prudential Commodities Fund ICICI Prudential | Sectoral / Thematic | 0.22% | 56,748 | Unchanged |
Explore Tatva Chintan Pharma Chem changes →What funds bought and sold this month →All stocks A–Z →
Want to know what this means for your portfolio?
Owning Tatva Chintan Pharma Chem through several funds at once is common — and easy to miss. Sulekha Sen can check what your funds really hold and whether it fits your goals.
Book a free 30-min call →Data: each AMC’s SEBI-mandated monthly portfolio disclosure, Aug 2026 (compared with Jul 2026). Holdings change after month-end. Direct Plan – Growth schemes only; one row per scheme. Changes are measured by number of shares or units, not portfolio weight. Not investment advice, and not a recommendation to buy, sell or hold any security or scheme. Mutual fund investments are subject to market risks, read all scheme related documents carefully.